Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Langmuir. 2013 Aug 6;29(31):9734-43. doi: 10.1021/la401067d. Epub 2013 Jul 26.
Inflammation and shear stress can upregulate expression of cellular adhesion molecules in endothelial cells (EC). The modified EC surface becomes a mediating interface between the circulating blood elements and the endothelium, and grants opportunity for immunotherapy. In photodynamic therapy (PDT), immunotargeting might overcome the lack of selectivity of currently used sensitizers. In this study, we hypothesized that differential ICAM-1 expression modulates the effects of a drug targeted to surface ICAM-1. A novel porphycene-anti-ICAM-1 conjugate was synthesized and applied to treat endothelial cells from macro and microvasculature. Results show that the conjugate induces phototoxicity in inflamed, but not in healthy, microvascular EC. Conversely, macrovascular EC exhibited phototoxicity regardless of their state. These findings have two major implications; the relevance of ICAM-1 as a modulator of drug effects in microvasculature, and the potential of the porphycene bioconjugate as a promising novel PDT agent.
炎症和切应力可在上皮细胞(EC)中上调细胞黏附分子的表达。经过修饰的 EC 表面成为循环血液成分与内皮之间的中介界面,为免疫治疗提供了机会。在光动力疗法(PDT)中,免疫靶向可能克服目前使用的敏化剂缺乏选择性的问题。在这项研究中,我们假设 ICAM-1 的差异表达会调节靶向表面 ICAM-1 的药物的作用。我们合成了一种新型卟啉-抗 ICAM-1 缀合物,并将其应用于治疗大、小血管内皮细胞。结果表明,该缀合物可诱导炎症状态下的微血管内皮细胞发生光毒性,但对健康的微血管内皮细胞没有作用。相反,无论其状态如何,大血管内皮细胞均表现出光毒性。这些发现有两个主要意义:ICAM-1 作为微血管中药物作用调节剂的相关性,以及卟啉生物缀合物作为一种有前途的新型 PDT 药物的潜力。